JP2010521476A5 - - Google Patents

Download PDF

Info

Publication number
JP2010521476A5
JP2010521476A5 JP2009553689A JP2009553689A JP2010521476A5 JP 2010521476 A5 JP2010521476 A5 JP 2010521476A5 JP 2009553689 A JP2009553689 A JP 2009553689A JP 2009553689 A JP2009553689 A JP 2009553689A JP 2010521476 A5 JP2010521476 A5 JP 2010521476A5
Authority
JP
Japan
Prior art keywords
alkyl
hcv
hydrogen
inhibitor
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009553689A
Other languages
English (en)
Japanese (ja)
Other versions
JP5232178B2 (ja
JP2010521476A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/055893 external-priority patent/WO2008112473A1/en
Publication of JP2010521476A publication Critical patent/JP2010521476A/ja
Publication of JP2010521476A5 publication Critical patent/JP2010521476A5/ja
Application granted granted Critical
Publication of JP5232178B2 publication Critical patent/JP5232178B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009553689A 2007-03-14 2008-03-05 C型肝炎の治療のための化合物 Expired - Fee Related JP5232178B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US89488707P 2007-03-14 2007-03-14
US60/894,887 2007-03-14
US98947407P 2007-11-21 2007-11-21
US60/989,474 2007-11-21
PCT/US2008/055893 WO2008112473A1 (en) 2007-03-14 2008-03-05 Compounds for the treatment of hepatitis c

Publications (3)

Publication Number Publication Date
JP2010521476A JP2010521476A (ja) 2010-06-24
JP2010521476A5 true JP2010521476A5 (cg-RX-API-DMAC7.html) 2011-04-14
JP5232178B2 JP5232178B2 (ja) 2013-07-10

Family

ID=39477552

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009553689A Expired - Fee Related JP5232178B2 (ja) 2007-03-14 2008-03-05 C型肝炎の治療のための化合物

Country Status (19)

Country Link
US (1) US7547690B2 (cg-RX-API-DMAC7.html)
EP (1) EP2118109B1 (cg-RX-API-DMAC7.html)
JP (1) JP5232178B2 (cg-RX-API-DMAC7.html)
KR (1) KR20100015304A (cg-RX-API-DMAC7.html)
CN (1) CN101657455B (cg-RX-API-DMAC7.html)
AR (1) AR065772A1 (cg-RX-API-DMAC7.html)
AU (1) AU2008226639B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0808763A2 (cg-RX-API-DMAC7.html)
CA (1) CA2681093A1 (cg-RX-API-DMAC7.html)
CL (1) CL2008000751A1 (cg-RX-API-DMAC7.html)
CO (1) CO6180426A2 (cg-RX-API-DMAC7.html)
EA (1) EA016614B1 (cg-RX-API-DMAC7.html)
IL (1) IL200905A0 (cg-RX-API-DMAC7.html)
MX (1) MX2009009473A (cg-RX-API-DMAC7.html)
NZ (1) NZ579342A (cg-RX-API-DMAC7.html)
PE (1) PE20090648A1 (cg-RX-API-DMAC7.html)
TW (1) TW200848058A (cg-RX-API-DMAC7.html)
WO (1) WO2008112473A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200906129B (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2005049622A1 (ja) * 2003-11-19 2007-06-07 日本たばこ産業株式会社 5−5員縮合複素環化合物及びそのhcvポリメラーゼ阻害剤としての用途
US20070049593A1 (en) * 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
US7659263B2 (en) 2004-11-12 2010-02-09 Japan Tobacco Inc. Thienopyrrole compound and use thereof as HCV polymerase inhibitor
US7521443B2 (en) * 2006-05-17 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7642251B2 (en) * 2007-08-09 2010-01-05 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7652004B2 (en) * 2007-08-09 2010-01-26 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8143243B2 (en) * 2007-08-09 2012-03-27 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
MX2010005226A (es) * 2007-11-20 2010-05-27 Bristol Myers Squibb Co Inhibidores de ns5b de hcv de indolobenzazepina fusionados a ciclopropilo.
US8129367B2 (en) * 2007-11-21 2012-03-06 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US8124601B2 (en) 2007-11-21 2012-02-28 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
PL2238142T3 (pl) 2007-12-24 2012-11-30 Janssen R&D Ireland Makrocykliczne indole jako inhibitory wirusa zapalenia wątroby typu C
AU2009228337A1 (en) * 2008-03-27 2009-10-01 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
EP2268643B1 (en) * 2008-03-27 2014-08-06 Bristol-Myers Squibb Company Dioxolane and dioxolanone fused indolobenzadiazepine hcv ns5b inhibitors
EP2280978B1 (en) * 2008-03-27 2013-04-24 Bristol-Myers Squibb Company Pyrrolidine fused indolobenzadiazepine hcv ns5b inhibitors
US8133884B2 (en) * 2008-05-06 2012-03-13 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8143244B2 (en) * 2009-02-26 2012-03-27 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
PH12012501068A1 (en) * 2009-12-07 2013-02-04 Targacept Inc 3,6-diazabicyclo [3.1.1] heptanes as neuronal nicotinic acetylcholine receptor ligands
US8716275B2 (en) * 2011-10-20 2014-05-06 Bristol-Myers Squibb Company Compound for the treatment of hepatitis C
WO2014011863A1 (en) * 2012-07-12 2014-01-16 Targacept, Inc. Method of treatment with 3-cyclopropylcarbonyl-3,6-diazabicyclo[3.1.1]heptane
BR112015000714A2 (pt) * 2012-07-18 2017-06-27 Bristol Myers Squibb Holdings Ireland processos e intermediários para a preparação de (4bs,5ar)-12-ciclo-hexil-n-(n,n-dimetilsulfamoil)-3-metóxi-5a-((1r,5s)-3-metil-3,8-diazabiciclo[3.2.1]octano-8-carbonil)-4b,5,5a, 6-tetra-hidrobenzo [3,4]ciclopropa[5,6]azepino[1,2-a] indol-9-carboxamida
KR20180125960A (ko) 2016-03-15 2018-11-26 바이엘 크롭사이언스 악티엔게젤샤프트 동물 해충을 방제하기 위한 치환된 술포닐 아미드
TW201822637A (zh) 2016-11-07 2018-07-01 德商拜耳廠股份有限公司 用於控制動物害蟲的經取代磺醯胺類
CN110028510A (zh) * 2019-05-22 2019-07-19 南京合巨药业有限公司 一种3-甲基-3,6-二氮杂-双环[3,1,1]庚烷二盐酸盐的制备方法
CN114641467A (zh) 2019-11-07 2022-06-17 拜耳公司 用于防治动物有害物的取代的磺酰胺
US12274700B1 (en) 2020-10-30 2025-04-15 Accencio LLC Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1719773E (pt) 2004-02-24 2009-06-03 Japan Tobacco Inc Compostos heterotetracíclicos fundidos e a sua utilização como inibidores da polimerase do hcv
US7348425B2 (en) 2004-08-09 2008-03-25 Bristol-Myers Squibb Company Inhibitors of HCV replication
US7153848B2 (en) 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
CA2585113A1 (en) 2004-10-26 2006-05-04 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Tetracyclic indole derivatives as antiviral agents
GB0518390D0 (en) 2005-09-09 2005-10-19 Angeletti P Ist Richerche Bio Therapeutic compounds
US7399758B2 (en) 2005-09-12 2008-07-15 Meanwell Nicholas A Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7473688B2 (en) 2005-09-13 2009-01-06 Bristol-Myers Squibb Company Indolobenzazepine HCV NS5B inhibitors
US7456165B2 (en) 2006-02-08 2008-11-25 Bristol-Myers Squibb Company HCV NS5B inhibitors
GB0608928D0 (en) 2006-05-08 2006-06-14 Angeletti P Ist Richerche Bio Therapeutic agents
US7456166B2 (en) * 2006-05-17 2008-11-25 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7521441B2 (en) 2006-05-22 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
CN101490054B (zh) 2006-05-25 2012-05-16 百时美施贵宝公司 环丙基稠合的吲哚并苯并氮杂*hcv ns5b抑制剂
WO2007140200A2 (en) 2006-05-25 2007-12-06 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
US7452876B2 (en) 2006-06-08 2008-11-18 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors

Similar Documents

Publication Publication Date Title
JP2010521476A5 (cg-RX-API-DMAC7.html)
JP2010515752A5 (cg-RX-API-DMAC7.html)
JP2010521481A5 (cg-RX-API-DMAC7.html)
JP2010521484A5 (cg-RX-API-DMAC7.html)
JP2010521483A5 (cg-RX-API-DMAC7.html)
HRP20110194T1 (hr) Ciklopropil fuzionirani indolobenzazepini kao inhibitori hcv ns5b
US8426458B2 (en) Hepatitis C Virus inhibitors
US8420686B2 (en) Linked diimidazole antivirals
US8703938B2 (en) Hepatitis C virus inhibitors
JP2012504632A5 (cg-RX-API-DMAC7.html)
JP2010510234A5 (cg-RX-API-DMAC7.html)
US9060971B2 (en) Combination pharmaceutical agents as inhibitors of HCV replication
US8314135B2 (en) Linked dibenzimidazole antivirals
JP2012512169A5 (cg-RX-API-DMAC7.html)
JP2012504132A5 (cg-RX-API-DMAC7.html)
JP2011523651A5 (cg-RX-API-DMAC7.html)
JP2008530096A5 (cg-RX-API-DMAC7.html)
JP2011521965A5 (cg-RX-API-DMAC7.html)
JP2012528161A5 (cg-RX-API-DMAC7.html)
MY146123A (en) Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatment using the same
AR065772A1 (es) Compuestos de indolobenzazepina para el tratamiento de la hepatitis c. composiciones farmaceuticas.
JP2012504126A5 (cg-RX-API-DMAC7.html)
JP2012511004A5 (cg-RX-API-DMAC7.html)
WO2004014313A3 (en) Combination pharmaceutical agents as inhibitors of hcv replication
JP2010509376A5 (cg-RX-API-DMAC7.html)